Kinfo
Pavella Therapeutics Inc. logo

Pavella Therapeutics Inc.

PVLANASDAQHealthcare·US · USD
$154.92
+6.71 (+4.53%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap2.13B USD
Enterprise value1.88B USD
Trailing P/E13.69
Forward P/E-21.74
PEG ratio0.22
Price / sales0.00
Price / book9.13
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-16.60%
Return on equity-34.25%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-49.30M USD
Diluted EPS-$4.17
Rev. growth (YoY)0.00%
Balance sheet
Total cash261.85M USD
Total debt20.38M USD
Debt / equity8.77
Current ratio28.88
Book value / share$16.23
Cash flow (TTM)
Operating cash flow-29.10M USD
Levered free cash flow-21.60M USD
Shares & price
Shares outstanding14.31M
Float9.58M
Held by institutions96.36%
Beta0.00
50-day MA$119.32
200-day MA$99.57
52-week high$155.00
52-week low$21.55
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-07-0.93-1.20−29.03%2026-03-24-0.40-1.00−150.00%2026-01-071.942.13+9.79%2025-11-10-0.85-1.03−21.18%
About Pavella Therapeutics Inc.

Pavella Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders. The primary function of the company is to research and advance treatments that address unmet medical needs in the realm of genetic diseases, leveraging advanced biotechnological innovations. The company plays a significant role in the health care and pharmaceutical sectors, differentiating itself with its commitment to precision medicine approaches and personalized therapies. By concentrating on niche areas that are often overlooked by larger pharmaceutical firms, Pavella Therapeutics Inc. aims to provide hope and potential treatment options to patients with limited alternatives. In the financial markets, Pavella Therapeutics holds a distinctive position as a cutting-edge firm with the potential to drive significant impacts within its specialized domain. The company's activities contribute to the broader biotechnology landscape by enhancing understanding of genetic conditions and supporting the development of targeted biotherapeutic solutions.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Wesley H. Kaupinen
Employees
29
Headquarters
Wayne, PA, United States

Frequently asked questions about Pavella Therapeutics Inc.